Brandon Canty Email

Clinical Research Associate . inmunebio.com

La Jolla, CA

Location

Current Roles

Employees:
28
Revenue:
$4.3M
About
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient's immune system to treat cancer. INKmune, the company's lead product, primes patient's NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease. Media coverage provided for informational purposes only and third party links provided as a resource. INmune Bio does not control the content of third parties. XPro1595, Quellor, LIVNate, INB03, INKmune and other drug candidates, have not yet been shown to be safe or effective, and has not been approved by any regulatory body.
inmunebio.com Address
225 NE Mizner Blvd
La Jolla, CA
United States
inmunebio.com Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.